Clinical TrialJul 20, 2026, 06:03 AM
Greenwich LifeSciences FLAMINGO-01 trial design approved, success up
AI Summary
Greenwich LifeSciences announced significant positive updates for its FLAMINGO-01 Phase III clinical trial for GLSI-100, an immunotherapy for breast cancer. The FDA and EMA have approved planned modifications to the study design, which are expected to more than double the enrollment rate by including all HLA types. Preliminary data from the fully enrolled non-HLA-A*02 open-label arm shows a 70-80% reduction in recurrence rates, and the new design substantially increases the probability of a successful BLA filing at the first interim analysis to over 85%. The company also reported a Q2 2026 cash balance of approximately $8.9 million and a manageable burn rate.
Key Highlights
- FDA and EMA approved significant modifications to the FLAMINGO-01 Phase III trial design.
- Enrollment rate is expected to increase by 122% (2.22x faster) by including all HLA types.
- Preliminary analysis of the non-HLA-A*02 arm shows a 70-80% reduction in recurrence rate (HR 0.2-0.3).
- Probability of BLA filing at the first interim analysis increased from less than 20% to more than 85%.
- The trial is designed to detect a hazard ratio (HR) of 0.55, requiring 28 events for the first interim analysis.
- Q2 2026 cash balance was approximately $8.9 million, with an expected burn rate of $2-4 million per quarter.
- The potential market for GLSI-100 is estimated to double to $10 billion per year.
Price Impact
More from GLSI